JNJ — Q3 2026 Financial Report Analysis

A $5.5 billion talc charge wiped out the profit, but the drug business sped up

Johnson & Johnson's fiscal third quarter of 2026 (the three months ended September 27, 2026) shows two very different things at once. The business grew. Sales rose 5.9% to $25,399 million. Operational growth, which strips out currency swings, was 6.0%, up from 5.6% in the second quarter. The reported profit, though, nearly disappeared. Net earnings fell 95.9% to $210 million and diluted earnings per share (EPS, profit divided by the number of shares) fell to $0.09 from $2.12.

Almost all of that gap comes from one decision. In July, J&J proposed a $5.5 billion settlement of roughly 76,000 remaining ovarian-cancer talc lawsuits and booked a $5,519 million pre-tax litigation charge this quarter. A second, smaller hit came from buying two early-stage biotech programs, Firefly Bio and a deal with Sail Biomedicines. J&J counts that cost even in its "adjusted" profit, so even the cleaned-up figure fell.

This analysis is based on the earnings release and financial schedules J&J furnished on October 13, 2026 (Form 8-K, Exhibits 99.1 and 99.2). The full 10-Q quarterly report isn't filed yet. Cash-flow statement detail and full management commentary (MD&A) will come with it.

At a glance

• $5,519 million talc charge. It accounts for about 72% of the gap between reported pre-tax profit ($34 million) and adjusted pre-tax profit ($7,672 million). No cash goes out yet: the first payment, of no more than $3 billion, is due in 2027.
• Adjusted EPS of $2.59, down 7.5%. The decline is mostly the roughly $1 billion Firefly research charge. J&J's own adjusted figure includes it, so this number understates how the underlying business did.
• TREMFYA +$972 million vs STELARA −$854 million. In Q2, J&J's newer immunology drug covered 94% of what its older blockbuster lost. In Q3 it more than covered it. That is the main reason the medicines business grew 7.9% operationally, its fastest pace this year.

The numbers

*J&J doesn't report an "operating income" line. Operating margin here is sales minus cost of products sold, selling/marketing/admin expense and R&D, divided by sales. That is the "pre-tax operating margin" definition J&J uses in its own guidance, and the same basis as our Q2 report. It leaves out the talc charge (booked in "other expense"), the $339 million research write-down and restructuring. It does include the Firefly research cost, which is why it fell. "Adjusted" figures are J&J's non-GAAP measures. They exclude amortization of acquired intangibles (the accounting write-down of patents and rights bought in past deals) and special items such as litigation and restructuring.

Where the profit went: four lines below gross profit

Gross profit, what's left after the cost of making the products, rose 3.7% to $17,302 million. Profit then shrinks on four lines further down the statement:

Talc. On July 27, J&J announced a proposed settlement of the remaining ovarian talc claims. It came after the federal court overseeing the combined lawsuits ruled that plaintiffs hadn't shown the products caused any particular claimant's cancer. J&J commits $5.5 billion in per-claim payments: no more than $3 billion in 2027, nothing more before 2028. The deal only takes effect if at least 95% of remaining claimants take part. Until then the charge is J&J's estimate of a settlement, not money already paid. J&J also still says its talc products are safe. The $5,519 million pre-tax "litigation related" item in the reconciliation is essentially this settlement.

Firefly and Sail. On July 29, J&J completed its $1 billion cash purchase of Firefly Bio, which is developing antibody-linked drugs that break down cancer-driving proteins. J&J accounted for it as an asset acquisition. In plain terms: because Firefly is an early-stage research platform rather than an operating business, the $1 billion is expensed straight away as in-process R&D instead of sitting on the balance sheet. J&J said the charge would land in Q3. R&D expense rose $980 million this quarter, almost exactly that size. The 10-Q will confirm the line-by-line split. The same day, J&J agreed to make initial payments of $785 million to Sail Biomedicines, including a $465 million equity stake, with an option to buy the company for $2.58 billion.

Tax. The provision flipped to a $176 million benefit, a negative effective tax rate of −517.6%. A tax rate calculated on $34 million of pre-tax profit isn't meaningful. On the adjusted basis the rate was 17.4%, down from 19.4%.

Medicines: TREMFYA now more than replaces STELARA

Innovative Medicine (J&J's prescription-drug segment) grew 7.9% operationally, with U.S. sales up 11.1%. J&J says STELARA alone took about 6.9 percentage points off the segment's growth. STELARA is its older psoriasis and Crohn's drug, now facing cheaper copies after losing patent protection. Without STELARA, segment sales would have grown about 14.6% on a reported basis ($16,041 million vs $13,993 million).

Two points matter here. First, TREMFYA's $972 million gain was 114% of STELARA's $854 million decline, so the hand-off from J&J's biggest-ever drug to its successor is done. STELARA is now a $716 million-a-quarter product, so the most it can still take away is shrinking each quarter. Second, the growth is spread across several products: oncology +16.4% and neuroscience +17.3%. CAPLYTA came with the 2025 Intra-Cellular Therapies acquisition. The weak spots are older products. Combined sales of pulmonary hypertension, infectious disease and cardiovascular drugs fell 9.9% to $2,560 million. U.S. OPSUMIT sales more than halved, to $193 million from $409 million. The release names OPSUMIT as a drag but doesn't give a reason. Expect that in the 10-Q.

MedTech slowed again

MedTech grew 2.5% operationally, down from 3.6% in Q2, and international MedTech sales were flat (+0.1%).

Surgery is the problem: down 1.0% operationally, and down 4.2% outside the U.S. Part of that is deliberate. J&J is in the final year of a restructuring that exits "certain non-strategic product lines" in Surgery. Electrophysiology (catheters that treat irregular heart rhythms) picked up a little, from 3.1% to 4.4%, driven by the U.S. (+7.0%). On the pipeline side, the FDA authorized the OTTAVA soft-tissue surgical robot this quarter, which J&J describes as the world's first robot built into the operating table. It won't affect sales until it's launched.

What the headline numbers hide

• Even "adjusted" EPS isn't a clean read this quarter. J&J's adjusted figures remove the talc charge, $1,240 million of intangible amortization, $369 million of Orthopaedics-separation costs, $195 million of restructuring and the $339 million IPR&D impairment. They don't remove the cost of buying research programs like Firefly. Our rough calculation: adding back the ~$1 billion Firefly charge (before any tax effect, divided by 2,448.6 million diluted shares) gives about $0.41 a share. On that basis adjusted EPS would have been roughly $3.00, up about 7% rather than down 7.5%. That figure is ours, not J&J's, and it ignores any Sail costs booked in the quarter.
• Gross margin slipped 1.5 points. Cost of products sold grew 10.9%, almost twice as fast as sales. The release doesn't explain why. Likely candidates are product mix and the tariff and separation costs our Q2 report flagged, but the reason won't be confirmed until the 10-Q.
• Cash is holding up. J&J estimates free cash flow (operating cash flow minus spending on plants and equipment) of about $15.1 billion for the first nine months, against $14,226 million a year earlier. Nine-month GAAP net earnings were only $10,979 million, because the talc charge is an accrual (a cost recorded now, paid later), not cash spent. The cash bill arrives from 2027.
• Tax helped adjusted EPS, buybacks didn't. The adjusted tax rate fell 2 points, to 17.4% from 19.4%, which cushioned the adjusted EPS decline. The diluted share count rose 0.8%, to 2,448.6 million, so per-share figures got no help from buybacks.
• Last year's quarter had its own one-offs. Q3 2025 included a $387 million gain on securities, and its "other" line was $478 million of income. The size of the year-on-year drop in reported profit overstates the deterioration.

Takeaway: Strip out the talc settlement and the Firefly purchase, both choices J&J made in July, and the quarter shows a drug business growing faster than in Q2 with the STELARA loss fully replaced. The weak part is MedTech, where growth fell to 2.5% and Surgery shrank. The bigger shift is in J&J's spending: it is now paying for future growth (and for ending past litigation) out of current profits, and 2027 will feel it more than 2026.

Guidance: raised, but from a lower base

J&J raised its 2026 outlook again, slightly. J&J doesn't give GAAP guidance, only adjusted figures. The "previous" column in its table is the July 29 update, which cut adjusted EPS by $0.64 for the Firefly ($0.46) and Sail ($0.18) deals. Our Q2 report quoted the guidance from before that cut.

The $0.06 increase is operational: adjusted operational EPS, which excludes currency, rose by the same amount. Nine-month adjusted EPS is $8.19, so the midpoint implies about $2.91 in Q4.

The figure to watch is 2027, not 2026. On July 29, J&J said the two deals would reduce 2027 adjusted EPS by about $1.36. Of that, $1.28 comes from Sail, assuming J&J exercises its $2.58 billion purchase option. That is about 12% of this year's guided $11.10. Add the talc payments starting in 2027 and the Orthopaedics separation, still pending. Next year's reported growth will depend heavily on deal accounting, not just on how the drugs and devices sell.

Did last time's read hold up?

Our Q2 report named two things to test in Q3: whether the tax rate settled nearer the mid-teens or high-teens, and whether Electrophysiology re-accelerated. On tax, the GAAP rate is meaningless this quarter because of the talc charge, but the adjusted rate came in at 17.4%, at the low end of that range. Electrophysiology did pick up, from 3.1% to 4.4% operational growth, but only modestly, and MedTech overall slowed further. Our Q2 read that "MedTech is the part to watch" still holds. Neither of the two Q3 surprises, the talc settlement and the guidance cut for the biotech deals, was on our Q2 watch list. Both came after our Q2 report's period, in the last week of July.

What to watch next

• The 10-Q (expected around October 21). It will show where the Firefly charge sits, why gross margin fell and why OPSUMIT dropped, plus full cash-flow figures.
• Talc participation. The settlement needs at least 95% of remaining claimants to sign up. If it falls short, the accrual and the timing could change.
• Whether MedTech growth stabilizes, and how OTTAVA's launch is paced. The Q4 implied adjusted EPS of about $2.91 leaves little room for another slowdown.